The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Korean Association for the Study of the Liver
2023-10-01
|
| Edice: | Clinical and Molecular Hepatology |
| Témata: | |
| On-line přístup: | http://e-cmh.org/upload/pdf/cmh-2023-0114.pdf |